Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease

Review (3 RCTs;n=646) found moderate‐certainty evidence that ustekinumab is probably effective for maintenance of clinical remission & response in people with moderate to severe Crohn's disease in remission without increased risk of adverse events (AEs) or serious AEs vs. placebo


Cochrane Database of Systematic Reviews